This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Alunbrig click here.

Resources

Tools and resources for ALUNBRIG(brigatinib)

Practical support for healthcare professionals
ALUNBRIG Key Facts Booklet

ALUNBRIG Key Facts Booklet

A booklet for healthcare professionals containing a summary of the ALUNBRIG efficacy, tolerability and standard dosing information

Download guide

Efficacy Overview Booklet

Efficacy & Tolerability Overview

A booklet for healthcare professionals, containing an overview of ALUNBRIG key efficacy data, with general tolerability information

Download guide

Dosing Overview

Dosing Overview

Information on ALUNBRIG standard dosing as a quick reference for healthcare professionals

Download guide

Dose Modification Guide

Dosing Modification Guide

A summary of ALUNBRIG dose modification for the management of adverse events

Download guide

Publications

Kim DW et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase positive non-small cell lung cancer: a randomized, multicenter phase II trial (ALTA). J Clin Oncol 2017;35:2490-8.

Request paper from Takeda Medical Information

Practical support for patients
Patient Brochure

Patient Brochure

A guide for patients on what ALUNBRIG is, practical advice including how to take, and advice on the management of side effects

Download guide

Expert opinion

Expert opinion - NICE recommendation for ALUNBRIG

Watch Dr Sanjay Popat (Medical Oncologist, The Royal Marsden Hospital, London) discuss the significance of this positive decision for ALK+ aNSCLC adult patients currently receiving crizotinib.

Watch video

Unmet need in advanced non-small cell lung cancer post crizotinib

Watch Prof. Marianne Nicolson (Medical Oncologist from Aberdeen Royal Infirmary, Aberdeen, UK) discuss the unmet need in the treatment of advanced non-small cell lung cancer.

Watch video

Efficacy of ALUNBRIG

Watch Dr. Tom Newsom- Davis (Medical Oncologist from Chelsea and Westminster NHS Foundation Trust, London, UK) discuss the efficacy data for ALUNBRIG.

Watch video

Tolerability of ALUNBRIG

Watch Dr. Tom Newsom- Davis (Medical Oncologist from Chelsea and Westminster NHS Foundation Trust, London, UK) share his perspective on the ALUNBRIG tolerability profile.

Watch video

ALUNBRIG dosing

Watch Prof. Marianne Nicolson (Medical Oncologist from Aberdeen Royal Infirmary, Aberdeen, UK) discuss the recommended dosing for ALUNBRIG.

Watch video

Patient Alert Card
Patient Alert Card

Patient Alert Card

A Patient Alert Card must be given to all patients prior to them beginning their treatment with ALUNBRIG. They should be monitored for adverse reactions, especially pulmonary adverse reactions, and the dose adjusted or discontinued if necessary, particularly in the first 7 days of treatment.

The Patient Alert Card describes the signs and symptoms of these serious pulmonary adverse reactions and what patients, and the healthcare professionals involved in their medical care, should do in the event that they experience any of these effects during or after treatment with ALUNBRIG.

Download